Soticlestat (TAK-935)
Dravet Syndrome, Lennox-Gastaut Syndrome
Key Facts
About Takeda
Takeda is a global biopharmaceutical leader committed to delivering life-transforming treatments, with a strategic focus on rare diseases, oncology, neuroscience, and gastroenterology. Its position was solidified by the landmark $62 billion acquisition of Shire in 2019, which expanded its footprint in rare diseases and plasma-derived therapies. The company employs a modality-agnostic, externalized R&D strategy, leveraging deep internal expertise in biologics and small molecules while aggressively partnering to access cutting-edge science. Takeda's financial foundation is built on a portfolio of marketed products, with a disciplined capital allocation strategy aimed at fueling innovation and sustainable growth.
View full company profileAbout Takeda Pharmaceutical
Takeda Pharmaceutical is a purpose-driven, global biopharmaceutical leader with a mission to create better health for people and a brighter future for the world. Its strategy is built on a balanced, diverse portfolio across five core therapeutic areas and a commitment to translating advanced science into life-transforming treatments. The company's 2019 acquisition of Shire plc was a pivotal event, establishing its leadership in rare diseases and significantly expanding its global footprint. Takeda is now executing a transformation to strengthen competitiveness and accelerate future growth, focusing on innovation, operational excellence, and sustainability.
View full company profileTherapeutic Areas
Other Dravet Syndrome, Lennox-Gastaut Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| Soticlestat (OV935/TAK-935) | Ovid Therapeutics | Phase 3 |